Organon & Co. (OGN) 株式分析

企業概要

Organon & Co. operates within the healthcare sector, specifically functioning as a drug manufacturer with a primary focus on delivering women's health solutions. The enterprise achieves this through the development and distribution of prescription therapies and medical devices across a global footprint that includes the United States, Europe, Canada, Japan, China, Latin America, the Middle East, Russia, Africa, and the rest of Asia Pacific. As of the latest reporting period, the company maintains a market capitalization of 15.2 億ドル (1.52B) and employs approximately 10,000 人の従業員。The firm recorded an annual revenue of 62.2 億ドル (6.22B) for the trailing twelve months. These valuation and revenue figures indicate that Organon holds a significant position in the pharmaceutical landscape, though its current market cap relative to revenue suggests a specific valuation dynamic common in the biotech and healthcare industries.

財務健全性

The company generated a revenue of 62.2 億ドル (6.22B) and reported a net income of 1.87 億ドル (187.00M) alongside an EBITDA of 16.5 億ドル (1.65B) over the trailing twelve months. The substantial disparity between the gross revenue of 62.2 億ドル and the net income of 1.87 億ドル highlights a cost structure where operating expenses, including research and development, marketing, and general administration, consume a significant portion of top-line earnings before reaching the bottom line. Organon demonstrated financial flexibility with a free cash flow of 1.90 億ドル (190.12M), which provides the liquidity necessary for capital expenditures, debt servicing, or potential strategic acquisitions. Profitability analysis reveals a gross margin of 54.3%, an operating margin of 16.2%, and a profit margin of 3.0%. The gross margin indicates efficient production and supply chain management, while the narrowing to a 3.0% profit margin reflects the high fixed costs and R&D expenditures inherent in the drug manufacturing industry. On the balance sheet, the company holds 57.4 億ドル (574.00M) in cash against a total debt load of 88.0 億ドル (8.80B). This configuration results in a debt-to-equity ratio of 1170.21, indicating a highly leveraged financial structure that relies heavily on equity financing or asset backing to support its obligations. Liquidity is supported by a current ratio of 1.82, suggesting the company possesses sufficient current assets to cover its short-term liabilities with a comfortable cushion. Return on equity stands at 30.6% while return on assets is 6.2%, metrics that reveal management's effectiveness in generating returns relative to the shareholders' equity and the total asset base utilized.

バリュエーション評価

Valuation multiples show a trailing P/E ratio of 8.11 compared to a forward P/E of 1.57. The significant divergence between these two metrics implies that the market expects a substantial shift in earnings trajectory or that current earnings include one-time items not reflected in the forward outlook, though without specific earnings growth data, the forward multiple suggests a very optimistic earnings expectation for the coming year. The price-to-book ratio is recorded at 2.02, indicating that the market values the company at twice its book value, which may reflect intangible assets such as intellectual property and brand value not captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.24 and an EV/EBITDA of 5.89. The low price-to-sales ratio suggests the stock is priced conservatively relative to its sales volume, while the EV/EBITDA of 5.89 provides a leverage-adjusted perspective on valuation that appears attractive when compared to industry peers. Price action over the past year shows a 52-week high of 15.85 ドル and a 52-week low of 5.83 ドル。To determine the current price position relative to this range, one must note the wide trading band, but without the specific current share price in the provided facts, the exact percentage deviation cannot be calculated; however, the range itself demonstrates significant historical volatility. The stock exhibits a beta of 0.57, which indicates that the share price is less volatile than the broader market, moving at roughly 43% of the market's amplitude.

Growth & Income

The company experienced a year-over-year revenue decline of -5.3%, while earnings growth is listed as N/A. The absence of positive earnings growth combined with declining revenue suggests a contraction in the core business unit or a significant restructuring impact, rather than an expansion phase. Regarding income, the company offers a dividend yield of 1.4% with a payout ratio of 47.2%. The payout ratio indicates that the company distributes nearly half of its earnings to shareholders, which must be evaluated against the context of recent revenue declines to assess long-term sustainability. Given the N/A status for earnings growth, the dividend yield serves as a primary return driver rather than capital appreciation from earnings expansion. The overall profile presents a mature, high-dividend stock that is currently navigating a period of revenue contraction with a leveraged balance sheet.